. Author manuscript; available in PMC: 2014 May 8.

Published in final edited form as: Clin Infect Dis. 2010 Jul 1;51(1):6–14. doi: 10.1086/653115

Table 3.

Change in Favorable Outcomes as a Function of Individual Study Characteristics

Study characteristic (no. of studies reporting)	Favorable outcomes improvement, % (95% CI)	P
HIV prevalence,^a % (13)	0.27 (−6.6 to 7.1)	.93
Mean age,^a years (13)	−20 (−35 to −3.8)	.019
Percentage female^a (12)	2.5 (−3.7 to 8.8)	.39
Mean no. of drugs in treatment regimen (10)	0.21 (−14.9 to 15.3)	.98
Mean no. of “likely active drugs” in treatment regimen (8)	5.5 (−8.6 to 20)	.38
Percentage who received fluoroquinolones^a (10)	3.7 (1.1 to 6.4)	.012
Percentage who received linezolid^a (10)	1.2 (−3.9 to 6.4)	.55
Percentage who underwent surgery^a (10)	1.9 (−4.9 to 8.7)	.65

NOTE. CI, confidence interval.

Per 10-unit change.